Moreover, since IFNβ is an FDA approved treatment of MS, application of exogenous IFNβ seems suitable to be tested in an infectious model, such as SIV-infected macaques, and if successful there, in HIV/HAND patients. Here, IFNB1 is linked to myeloid sarcoma.